Trending...
- TEAMSTERS STRIKE GREEN THUMB INDUSTRIES OVER UNFAIR LABOR PRACTICES
- New Slotozilla Project Explores What Happens When the World Goes Silent
- The Two Faces of Charles D. Braun: How the Novel, Posthumously Yours, Came to Life
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming April 13, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) securities between May 11, 2020 and November 4, 2020, inclusive (the "Class Period").
Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for LentiGlobin for sickle cell disease in the second half of 2021.
More on The PennZone
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to "feedback" from the FDA that requires the Company to provide additional data "to demonstrate drug product comparability" for LentiGlobin for sickle cell disease, as well as "COVID-19 related shifts and contract manufacturing organization COVID-19 impacts."
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased or otherwise acquired bluebird securities during the Class Period, you may move the Court no later than April 13, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Investors suffering losses on their bluebird investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for LentiGlobin for sickle cell disease in the second half of 2021.
More on The PennZone
- Assent Unveils Extended Producer Responsibility Packaging Solution to Simplify Compliance with Expanding Packaging Laws
- Governor Shapiro Named 2025 "Champion for Aging" at the Annual Connected Health & Safety Conference
- Steven Weisz of Art Imagined Photography Receives Two Honorable Mentions in the Prix de la Photo
- KatalisCoin: "Too Secure" for Bad Actors - Platform Embraces "Excessive Compliance" Criticism
- Keyanb Exchange Implements Enhanced Security Protocols Amid Industry-Wide Trust Challenges
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to "feedback" from the FDA that requires the Company to provide additional data "to demonstrate drug product comparability" for LentiGlobin for sickle cell disease, as well as "COVID-19 related shifts and contract manufacturing organization COVID-19 impacts."
On this news, bluebird's stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- TSWHZC Platform Combines Automated Portfolio Management with Proof of Reserves for Brazil Market Entry
- AureaVault Positions Digital Asset Infrastructure for Shifting Monetary Policy Environment
- JQRBT Unveils High-Speed Trading Infrastructure Designed for Growing Institutional Crypto Market
- One Provider Bringing Life-Saving Care to Philly One Text at a Time
- Global Gathering for MANHATTAN SHORT 2025 Features Top 10 Films
If you purchased or otherwise acquired bluebird securities during the Class Period, you may move the Court no later than April 13, 2021 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- NKSCX Responds to "Coordinated Smear Campaign" as Anonymous Critics Emerge Following Regulatory Milestones
- Broadway Gala Honored Also an Italian
- $ONI Listed on MEXC as ONINO Powers Europe's Tokenization Engine Into Public Platform Launch
- AZETHIO Crypto Exchange Whitepaper Reveals MPC-Secured Infrastructure Processing 1.2 Million Transactions Per Second
- CELOXFI Platform Demonstrates Advanced Security Architecture and Regulatory Framework
- Work 365 Launches PV 3.0: The Keystone Power App for Microsoft CSPs
- Local consultant shows small businesses how to turn red tape into real money
- The Inner Circle acknowledges, Erica S. Becker, DDS as a Pinnacle Professional Member Inner Circle
- Tour Napa Like a Local: Vines of Napa Valley Wine Passport AKA Vine Pass Unlocks Hidden Gems
- Dental Surgical Center Accepts Sedation Patients with Medicaid for MD, WV, PA and DC
- Can Invisalign Fix Cross Bites? Allentown Patients Find Answers at Exeter Smiles
- Sloan's Lake Dental Launches New Website to Enhance Patient Experience and Access to Modern Dental Care
- Only 3 Weeks Left till the Start of the OpenSSL Conference 2025
- ENTOUCH Completes $50 million Funding Round
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- Promising New Preclinical Therapy Offers Hope in the Development of Precision Medicine Treatments for Aggressive Cancers
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts